Dupilumab Treatment Leads to Clinical Asthma Remission in Patients With Uncontrolled Moderate-to-Severe Asthma With Type 2 Inflammation

Asthma treatment response is ascertained by improvement in ≥1 key asthma outcome (exacerbations/symptom control/lung function). This post hoc analysis of LIBERTY ASTHMA QUEST (NCT02414854) assessed dupilumab effect patients with uncontrolled, moderate-to-severe using a multicomponent endpoint representing various dimensions clinical remission. Clinical remission components (no exacerbations/5-item Control Questionnaire [ACQ-5] total score <1.5/post-bronchodilator FEV1 ≥80%) were at Week (Wk)24/Wk52 348 dupilumab-treated (200/300mg every 2 weeks combined) and 195 matched placebo-treated baseline post-bronchodilator <80%, FeNO ≥25ppb, eosinophils ≥150/μL. Higher percentages exacerbation-free vs placebo (Wk24: 83.3% 61.0%; Wk52: 72.7% 46.2%). Likewise, more an ACQ-5 <1.5 57.5% 27.2%; 43.1% 21.5%). Also, Wk24, 103 (29.6%) 15 (7.7%) exacerbation-free, <1.5, ≥80%, thereby achieving remission; Wk52, there 70 (20.1%) 9 (4.6%) patients, respectively. Among not remission, dupilumab- still had fewer exacerbations (adjusted annualized rate severe Wk24/Wk52: 0.63/0.56 1.51/1.46) improved lung function control (LS mean change 0.20/0.22L 0.02/0.03L [FEV1] −1.33/−1.51 −1.00/−1.11 [ACQ-5 score]). Dupilumab could enable uncontrolled to achieve stringent novel substantially reduced who did